Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,570 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Period B Clear all
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer

NCT01896856
View directory record Official record
Conditions
Previously Treated Metastatic Colorectal Cancer
Interventions
SGI-110 Dose Escalation, Regorafenib, TAS-102, SGI-110, Irinotecan
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

To Assess the Safety of a Sunscreen Product

NCT02803320
View directory record Official record
Conditions
Sunscreening Agents
Interventions
SPF 50 Y65 110 (BAY 987516)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Investigate the Effects of Diltiazem on the Pharmacokinetics of Naloxegol

NCT01594619
View directory record Official record
Conditions
Drug Induced Constipation
Interventions
Naloxegol, Diltiazem XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 26, 2026, 4:34 AM EDT
Active, not recruiting Phase 1 Interventional

CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL

NCT00586391
View directory record Official record
Conditions
B Cell Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia
Interventions
CD19CAR-28-zeta T cells, Ipilimumab
Genetic · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2029
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MK-2225 in Healthy Participants (MK-2225-003)

NCT06643390
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
MK-2225, Placebo
Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Miami, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment: Spanish Language Homes

NCT05159596
View directory record Official record
Conditions
Dementia, Mild Cognitive Impairment, Alzheimer Disease
Interventions
In-Home Technology System, Limited In-Home Technology
Device
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy Participants

NCT03682380
View directory record Official record
Conditions
Healthy
Interventions
Seltorexant High Dose, Seltorexant Low Dose
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effect of Food on Pirtobrutinib (LOXO-305) in Healthy Participants

NCT06180980
View directory record Official record
Conditions
Healthy
Interventions
Pirtobrutinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 1 Interventional

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

NCT05375903
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
Interventions
UGN-301, UGN-201, Gemcitabine
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Little Rock, Arkansas • Los Angeles, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Investigate the Effects of Ketoconazole on the Pharmacokinetics of NKTR-118

NCT01520896
View directory record Official record
Conditions
Bioavailability, Healthy Volunteers, Drug- Drug Interactions
Interventions
NKTR-118, Ketoconazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 26, 2026, 4:34 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer

NCT04931017
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Biopsy, Biospecimen Collection, Bronchoscopy, Extended Release Metformin Hydrochloride, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 26, 2026, 4:34 AM EDT
Recruiting Not applicable Interventional

Remote Cardiac Rehab for Adolescents With Congenital Heart Disease

NCT06015191
View directory record Official record
Conditions
Congenital Heart Disease in Children
Interventions
Remote Cardiac Rehabilitation, Active Control
Behavioral
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
12 Years to 19 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 26, 2026, 4:34 AM EDT
Terminated Phase 3 Interventional Results available

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT04408755
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
45
States / cities
Fort Smith, Arkansas • La Jolla, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654

NCT06389955
View directory record Official record
Conditions
Healthy
Interventions
TP 3654
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 26, 2026, 4:34 AM EDT
Active, not recruiting Not applicable Interventional

Miro-randomized Trial for Optimizing a JITAI to Reduce Dietary Lapses in Obesity Treatment

NCT04784585
View directory record Official record
Conditions
Obesity
Interventions
JITAI Enhanced Education Intervention Option, JITAI Self-Efficacy Intervention Option, JITAI Motivation Intervention Option, JITAI Self-Regulation Intervention Option, JITAI Generic Risk Alert Intervention Option (Active Comparator), Online Behavioral Obesity Treatment, JITAI No Treatment Intervention Option
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184

NCT01953835
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
GSK2586184 standard formulation, Simvastatin, Rosuvastatin, GSK2586184 new formulation
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

NCT03719326
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer, Ovarian Cancer
Interventions
Etrumadenant, IPI-549, Pegylated liposomal doxorubicin (PLD), nanoparticle albumin-bound paclitaxel (NP)
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
20
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Not applicable Interventional

Noom Coach for Bariatric Health

NCT03887078
View directory record Official record
Conditions
Obesity
Interventions
Noom Coach for Bariatric Health
Behavioral
Lead sponsor
Noom Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants

NCT02908685
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Placebo, Risdiplam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 25 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Palo Alto, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Norgestrel 75 mcg on Cervical Mucus and Ovarian Activity During Perfect Use, After One Delayed Intake and After a Missed Pill

NCT03585712
View directory record Official record
Conditions
Contraception
Interventions
Norgestrel 0.075 mg
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Sacramento, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 26, 2026, 4:34 AM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine

NCT07010471
View directory record Official record
Conditions
Developmental and Epileptic Encephalopathy 1
Interventions
1.0mg/kg/day PRAX-562, 1.5mg/kg/day PRAX-562, Placebo
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
2 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
La Jolla, California • Gulf Breeze, Florida • Chevy Chase, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 26, 2026, 4:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Lu AG06474 in Healthy Young Men

NCT05003687
View directory record Official record
Conditions
Healthy
Interventions
Lu AG06474, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 26, 2026, 4:34 AM EDT
Withdrawn Phase 2 Interventional

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

NCT03035630
View directory record Official record
Conditions
Clear-cell Renal Cell Carcinoma, RCC, Kidney Cancer, Clear-cell Kidney Carcinoma
Interventions
Avelumab, Sunitinib
Drug
Lead sponsor
Guru Sonpavde
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 26, 2026, 4:34 AM EDT
Recruiting Not applicable Interventional

Transcutaneous Auricular Vagus Nerve Stimulation Device in CKD Population

NCT05981183
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Transcutaneous electrical nerve stimulation unit (TENS)
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 26, 2026, 4:34 AM EDT